scholarly journals Low-Grade Gliomas: Six-month Tumor Growth Predicts Patient Outcome Better than Admission Tumor Volume, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient

Radiology ◽  
2009 ◽  
Vol 253 (2) ◽  
pp. 505-512 ◽  
Author(s):  
Gisele Brasil Caseiras ◽  
Olga Ciccarelli ◽  
Daniel R. Altmann ◽  
Christopher E. Benton ◽  
Daniel J. Tozer ◽  
...  
Keyword(s):  
Patient Outcome ◽  
Diffusion Coefficient ◽  
Apparent Diffusion Coefficient ◽  
Tumor Growth ◽  
Blood Volume ◽  
Cerebral Blood Volume ◽  
Tumor Volume ◽  
Low Grade ◽  
Apparent Diffusion ◽  
Better Than

scholarly journals Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma

2019 ◽  
Vol 8 (11) ◽  
pp. 2007
Author(s):  
Cuccarini ◽  
Aquino ◽  
Gioppo ◽  
Anghileri ◽  
Pellegatta ◽  
...  
Keyword(s):  
Diffusion Coefficient ◽  
Dendritic Cell ◽  
Apparent Diffusion Coefficient ◽  
Blood Volume ◽  
Cerebral Blood Volume ◽  
Standard Treatment ◽  
Inflammatory Responses ◽  
Therapeutic Benefit ◽  
Potential Contribution ◽  
Apparent Diffusion

Evaluating changes induced by immunotherapies (IT) on conventional magnetic resonance imaging (MRI) is difficult because those treatments may produce inflammatory responses. To explore the potential contribution of advanced MRI to distinguish pseudoprogression (PsP) and true tumor progression (TTP), and to identify patients obtaining therapeutic benefit from IT, we examined aMRI findings in newly diagnosed glioblastoma treated with dendritic cell IT added to standard treatment. We analyzed longitudinal MRIs obtained in 22 patients enrolled in the EUDRACT N° 2008-005035-15 trial. According to RANO criteria, we observed 18 TTP and 8 PsP. Comparing MRI performed at the time of TTP/PsP with the previous exam performed two months before, a difference in cerebral blood volume ΔrCBVmax ≥ 0.47 distinguished TTP from PsP with a sensitivity of 67% and specificity of 75% (p = 0.004). A decrease in minimal apparent diffusion coefficient rADCmin (1.15 vs. 1.01, p = 0.003) was observed after four vaccinations only in patients with a persistent increase of natural killer cells (response effectors during IT) in peripheral blood. Basal rADCmin > 1 was independent predictor of longer progression free (16.1 vs. 9 months, p = 0.0001) and overall survival (32.8 vs. 17.5 months, p = 0.0005). In conclusion, rADC predicted response to immunotherapy and survival; Apparent Diffusion Coefficient (ADC) and Cerebral Blood Volume (CBV) modifications over time help differentiating PsP from TTP at onset.

Sign in / Sign up

Export Citation Format

Share Document